Immune monitoring of human gene therapy trials: Potential application to leukemia and lymphoma

Blood Cells, Molecules, and Diseases

Volumn 31, Issue 1, 2003, Pages 63-71

  Whiteside, Theresa L ^a   Gooding, William ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; CANCER ANTIBODY; CYTOKINE; PEPTIDE; TETRAMER;

ANALYTIC METHOD; ANTIGEN SPECIFICITY; BINDING AFFINITY; CLINICAL TRIAL; DENDRITIC CELL; FLOW CYTOMETRY; GENE THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; LEUKEMIA; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; MELANOMA; METASTASIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION;

EID: 0037675805     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-9796(03)00064-0     Document Type: Article

References (23)

1. H. Okada, F.S. Lieberman, H.D. Edington, T.F. Witham, M.J. Wargo, Q. Cai, E.M. Elder, T.L. Whiteside, S.C. Schold, I.F. Pollack, Interleukin-4 gene transfected autologous tumor cell vaccine in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy, J. Neurooncol. (2003) in press.
2. Marchand M., van Baren N., Weynants P., Brichard V., Dreno B., Tessier M.H., Rankin E., Parmiani G., Arienti F., Humblet Y., Bourlond A., Vanwijck R., Lienard D., Beauduin M., Dietrich P.Y., Russo V., Kerger J., Masucci G., Jager E., De Greve J., Atzpodien J., Brasseur F., Coulie P.G., van der Bruggen P., Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer. 80:1999;219-230.
3. Jager E., Ringhoffer M., Altmannsberger M., Arand M., Karbach J., Jager D., Oesch F., Knuth A. Immunoselection in vivo independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma . Int. J. Cancer. 71:1997;142-147.
4. Parmiani G., Castelli C., Dalerba P., Mortarini R., Rivoltini L., Marincola R.M., Anichini A. Cancer immunotherapy with peptide-based vaccines where are we going? J. Natl. Cancer Inst. 94:2002;805-818.
5. Whiteside T.L., Hank J.A. Monitoring of immunologic therapies. Rose R.N., Hamilton R.G., Detrick B. Manual of Clinical Laboratory Immunology. 6th ed: 2002;1108-1117 ASM, Washington, DC.
6. Czerkinsky C.C., Nilsson L.A., Nygren H., Ouchterlony O., Tankowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods. 65:1983;109-121.
7. Suni M.A., Picker L.J., Maino V.C. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J. Immunol. Methods. 212:1998;89-98.
8. Altman J.D., Moss P.A.H., Goulder P. Jr., Banouch D.H., McHeyzen-Williams M.G., Bell J.I., McMichael A.J., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
9. T.L. Whiteside, Y. Zhao, T. Tsukishiro, E.M. Elder, W. Gooding, J. Baar, Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin. Cancer Res., 9, (2003) 641-649.
10. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis alpha. J. Exp. Med. 179:1994;1109-1118.
11. Asai T., Storkus W.J., Whiteside T.L. Evaluation of the modified ELISPOT assay for interferon-γ production in monitoring of cancer patients receiving anti-tumor vaccines. CDLI. 7:2000;145-154.
12. Clay T.M., Hobeika A.C., Mosca P.J., Lyerly K.H., Morse M.A. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer. Res. 7:2001;1127-1135.
13. Walker E., Smith J.W. III, Hu H.-M., Romero P., Fox B.A., Urba W.J. Immunomonitoring of gp100 peptide (209-2M) immunized melanoma patients comparative analysis using ELISPOT detection, cytokine flow cytometry and a tetramer binding assay . AACR Proc. 43:2002;82.
14. Jameson J., Cruz J., Ennis F.A. Human cytotxic T-lymphocyte repertoire to influenza A virus. J. Virol. 72:1998;8682-8689.
15. Pitcher C.J., Quittner C., Peterson D.M., Connors M., Koup R.A., Maino V.C., Picker L.J. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5:1999;518-525.
16. + peripheral blood T lymphocytes of patients with melanoma. Clin. Cancer Res. 7:2001;947-957.
17. Whiteside T.L., Rabinowich H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol. Immunother. 46:1998;175-184.
18. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., Johnson D., Swetter S., Thompson J., Greenberg P.D., Roederer M., Davis M.M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:1999;677-685.
19. Reichert T.E., Strauss L., Wagner E.M., Gooding W., Whiteside T.L. Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin. Cancer Res. 8:2002;3137-3145.
20. Jaeger E., Ringhoffer M., Dienes H.P., Arand M., Karbach J., Jaeger D., Ilsemann C., Hagedorn M., Oesch F., Knuth A. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma associated peptides in vivo. Int. J. Cancer. 67:1996;54-62.
21. Gjertsen M.K., Buanes T., Rosseland A.R., Bakka A., Gladhaug I., Soreide O., Eriksen J.A., Moller M., Baksaas I., Lothe R.A., Saeterdal I., Gaudernack G. Intradermal ras peptide vaccination with granulocyte-machrophage colony-stimulating factor as adjuvant clinical and immunological responses in patients with pancreatic adenocarcinoma . Int. J. Cancer. 92:2001;441-450.
22. Jager E., Gnjatic S., Nagata Y., Stockert E., Jager D., Karbach J., Neumann A., Rieckenberg J., Chen Y.T., Ritter G., Hoffmann E., Arand M., Old L.J., Knuth A. Induction of primary NY-ESO-1 immunity CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers . Proc. Natl. Acad. Sci. USA. 97:2000;12198-12203.
23. Black C.A. Delayed type hypersensitivity current theories with an historic perspective . J. Dermatol. Online. 5 (1):1999;7. (review).